SecBot SecBot

INM drug pipeline

$19.87
+6.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePreclinical (IND-enabling)
Time to marketUnknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.

MT-001 anti-PACAP monoclonal antibody Updated Jul 2

What to watch

MT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.

Bull case
  • PACAP is a newly validated migraine target, Lundbeck's bocunebart (also anti-PACAP) succeeded in a Phase 2b study, de-risking the mechanism (source: fiercebiotech.com)
  • The $290M oversubscribed PIPE (led by Fairmount, with a16z, Janus Henderson, Commodore Capital) funds operations through 2028, unusual depth for a preclinical asset (source: biospace.com)
  • Designed for convenient subcutaneous dosing with best-in-class claims based on in vitro potency vs. benchmarks (source: inmedpharma.com press release)
Bear case
  • No human data exists, MT-001 is still preclinical and has not filed an IND. Phase 2a data is not expected until 2028, years away from any pivotal catalyst (source: benzinga.com)
  • Earlier anti-PACAP programs failed: Amgen's AMG 301 (PAC1 receptor antagonist) and Eli Lilly's LY3451838 both flopped in Phase 2 (source: p05.org)
  • Intense competition, Lundbeck's bocunebart is already in Phase 2b with positive data; Slate Medicines launched with $130M; Vedana debuted with $46M; all targeting PACAP (source: fiercebiotech.com, biopharmadive.com)
● neutral
Impact
PhasePreclinical
Time to marketUnknown — preclinical stage; best-case scenario Phase 1 data in 2027, then Phase 2/3 would take several more years. Realistically 5+ years from now if successful.

MT-002 anti-CGRP x PACAP bispecific antibody Updated Jul 2

What to watch

MT-002 is very early-stage and won't generate human data until at least late 2027. The nearer-term story for INM is the reverse merger with Mentari Therapeutics closing (target Q4 2026), the $290M PIPE funding, and MT-001's FIH filing. Existing INM shareholders face extreme dilution (~1.51% of the combined entity). This is a pre-revenue, preclinical-stage binary with a long timeline, not a trading catalyst in its own right.

Bull case
  • Potentially first-in-class bispecific antibody targeting two validated migraine pathways (CGRP and PACAP) simultaneously, could address the ~2/3 of patients with suboptimal response to existing anti-CGRP-only therapies.
  • Merger backed by $290M in committed PIPE financing from institutional investors, funding MT-001 and MT-002 programs through 2028, removing near-term cash concerns.
  • Massive addressable market: CGRP inhibitors market projected to reach $9-12.5B by 2033; MT-002 targets the large unmet need of non-responders.
Bear case
  • Preclinical, no human data yet; high risk of clinical failure. Only ~10% of preclinical CNS/migraine assets make it to FDA approval.
  • Existing INM shareholders diluted to ~1.51% of the combined company post-merger, the stock is essentially a new entity with a different business.
  • Intensely competitive landscape: 4 approved anti-CGRP antibodies (Aimovig, Emgality, Ajovy, Vyepti) plus oral gepants are entrenched, and Lundbeck's anti-PACAP antibody bocunebart (Lu AG09222) is already in Phase 2b with positive data, years ahead of MT-002.